Balchem (BCPC) Scheduled to Post Earnings on Friday

Balchem (NASDAQ:BCPC) is set to release its earnings data before the market opens on Friday, May 3rd. Analysts expect Balchem to post earnings of $0.95 per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Balchem (NASDAQ:BCPC) last announced its quarterly earnings data on Friday, February 16th. The basic materials company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.93 by $0.02. The firm had revenue of $228.70 million during the quarter, compared to analysts’ expectations of $234.66 million. Balchem had a return on equity of 10.69% and a net margin of 11.77%. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.66 EPS. On average, analysts expect Balchem to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Balchem Price Performance

Shares of NASDAQ BCPC opened at $138.50 on Friday. The stock has a market capitalization of $4.47 billion, a PE ratio of 41.34, a P/E/G ratio of 4.38 and a beta of 0.71. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.12 and a quick ratio of 1.38. The business has a fifty day moving average price of $152.40 and a two-hundred day moving average price of $139.85. Balchem has a fifty-two week low of $110.74 and a fifty-two week high of $159.52.

Analysts Set New Price Targets

Separately, StockNews.com cut Balchem from a “buy” rating to a “hold” rating in a report on Thursday.

Insider Activity

In other news, SVP Michael Robert Sestrick sold 11,100 shares of Balchem stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $153.21, for a total value of $1,700,631.00. Following the transaction, the senior vice president now owns 6,736 shares in the company, valued at approximately $1,032,022.56. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, SVP Michael Robert Sestrick sold 11,100 shares of Balchem stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $153.21, for a total value of $1,700,631.00. Following the transaction, the senior vice president now owns 6,736 shares in the company, valued at approximately $1,032,022.56. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Theodore L. Harris sold 34,350 shares of Balchem stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $154.29, for a total value of $5,299,861.50. Following the completion of the transaction, the chief executive officer now owns 66,412 shares in the company, valued at approximately $10,246,707.48. The disclosure for this sale can be found here. In the last quarter, insiders have sold 76,630 shares of company stock worth $11,843,249. Insiders own 1.77% of the company’s stock.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.